scholarly journals Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory

2017 ◽  
Vol 11 ◽  
pp. 117822341769452 ◽  
Author(s):  
Monita Karmakar ◽  
Sharrel L Pinto ◽  
Timothy R Jordan ◽  
Iman Mohamed ◽  
Monica Holiday-Goodman
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Self Efficacy ◽  
Breast Cancer Survivors ◽  
Protection Motivation Theory ◽  
Protection Motivation ◽  
Motivation Theory ◽  
Aromatase Inhibitor Therapy ◽  
Morisky Scale

The purpose of this observational study was to determine if the Protection Motivation Theory could predict and explain adherence to aromatase inhibitor (AI) therapy among breast cancer survivors. Purposive sampling was used to identify 288 survivors who had been prescribed AI therapy. A valid and reliable survey was mailed to survivors. A total of 145 survivors completed the survey. The Morisky scale was used to measure adherence to AI. The survivors reported a mean score of 6.84 (±0.66) on the scale. Nearly 4 in 10 survivors (38%) were non-adherent. Adherence differed by age, marital status, insurance status, income, and presence of co-morbid conditions. Self-efficacy (r=0.485), protection motivation (r=0.310), and Response Efficacy (r=0.206) were positively and significantly correlated with adherence. Response Cost (r=-0.235) was negatively correlated with adherence. The coping appraisal constructs were statistically significant predictors medication adherence (β=0.437) with self-efficacy being the strongest significant predictor of adherence (β = 0.429).

scholarly journals The development of an arm activity survey for breast cancer survivors using the Protection Motivation Theory

BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
Teresa S Lee ◽  
Sharon L Kilbreath ◽  
Gerard Sullivan ◽  
Kathryn M Refshauge ◽  
Jane M Beith
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Protection Motivation Theory ◽  
Protection Motivation ◽  
Motivation Theory ◽  
Activity Survey

scholarly journals The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors

2019 ◽  
Vol 3 (3) ◽  
Author(s):  
Kevin T Liou ◽  
Tim A Ahles ◽  
Sheila N Garland ◽  
Q Susan Li ◽  
Ting Bao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer ◽  
Inhibitor Therapy ◽  
Cancer Center ◽  
Aromatase Inhibitor Therapy ◽  
Insomnia Severity

Abstract Background Cancer-related cognitive impairment is an emerging public health burden. Growing research suggests that sleep disturbances contribute to poor cognition. Our study aimed to evaluate the association between insomnia and cognitive impairment in breast cancer survivors. Methods We analyzed cross-sectional data from a cohort study of postmenopausal women with stage 0–III hormone receptor-positive breast cancer on aromatase inhibitor therapy. The study was conducted between November 2011 and April 2015 at an academic cancer center (Philadelphia, PA). Insomnia was assessed with the Insomnia Severity Index. Perceived cognitive impairment was assessed with the cognitive subscale of the Breast Cancer Prevention Trial Symptom Checklist. We used linear regression to evaluate the association between insomnia and perceived cognitive impairment. Results Among 1072 patients, 556 (51.9%) reported insomnia and 847 (79.0%) were bothered by cognitive symptoms (forgetfulness, difficulty concentrating, distractibility). Greater perceived cognitive impairment was reported by patients with mild insomnia (regression coefficient [β] = 0.35, 95% confidence interval [CI] = 0.23 to 0.46, P < .001), moderate insomnia (β = 0.51, 95% CI = 0.36 to 0.65, P < .001), and severe insomnia (β = 0.94, 95% CI = 0.67 to 1.21, P < .001), compared with those without insomnia. Greater perceived cognitive impairment was also associated with patients younger than 55 years (β = 0.30, 95% CI = 0.15 to 0.45, P < .001), taxane-based chemotherapy (β = 0.11, 95% CI = 0.004 to 0.22, P = .04), anxiety (β = 0.47, 95% CI = 0.30 to 0.64, P < .001), and depression (β = 0.65, 95% CI = 0.35 to 0.94, P < .001). Conclusions Among postmenopausal breast cancer survivors receiving aromatase inhibitor therapy, insomnia and cognitive impairment are prevalent and characterized by a graded association, in which severity of perceived cognitive impairment increases as insomnia severity increases. Our findings warrant further research to determine whether addressing sleep is a strategy to improve management of cancer-related cognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document